TheraPEA™, DSM Biomedical's novel biodegradable platform of Polyester Amide (PEA) polymers, enables the formulation of therapeutic solutions where they are needed most - in treatments of coronary artery disease, pain management, diabetes management, and for vision preservation. Our TheraPEA™ platform has proven compatibility with a wide range of active pharmaceutical ingredients and across different routes of administration to develop an optimal therapy for the patient.  

 The TheraPEA™ platform has a tunable degradation profile and offers many benefits over commonly used materials in this market, including:

• Broad compatibility with a wide range of small molecule and biological drugs due to their non-acidic degradation and low susceptibility to acylation. 
• Excellent biocompatibility, proven in multiple settings including ophthalmic, intravascular, and intra-articular applications.

Our biomedical polyurethanes have a long successful clinical history and give formulators a proven, customizable platform from which to create delivery of medications for systemic drug delivery with duration of several days to multiple months.  DSM’s extensive polymer expertise allows customization of both the bulk and surface chemistries for targeted compositions based on the pharmaceutical attributes and hydrophilicity requirements.